124863-79-2

Upstream product

• 124863-78-1 diethyl 4-(4-fluorophenyl)-2,6-diisopropyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 84-58-2 2,3-dicyano-5,6-dichloro-p-benzoquinone 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 122930-45-4 (E)-2-<(4-fluorophenyl)methylene>-4-methyl-3-oxopentanoic acid ethyl ester 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 202853-57-4 2,6diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-octenyl)pyridine 
• 202853-56-3 [4-(4-Fluoro-phenyl)-5-((E)-hept-1-enyl)-2,6-diisopropyl-pyridin-3-yl]-methanol 
• 202853-47-2 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-hexylpyridine 
• 202854-26-0 (+/-)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-pentyl-pyridine 
• 202857-39-4 propyltriphenylphosphonium bromide 
• 202853-25-6 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentylpyridine 
• 202857-53-2 4-(4-Fluoro-phenyl)-2,6-diisopropyl-3-((E)-2-methoxy-vinyl)-5-pentyl-pyridine 
• 334932-51-3 [4-(4-Fluoro-phenyl)-5-((E)-hex-1-enyl)-2,6-diisopropyl-pyridin-3-yl]-methanol 

Relevant academic research and scientific papers

Synthesis of d3-cerivastatin for use as internal standard in a LC/MS/MS method developed for quantitation of the drug in human serum

d3-Cerivastatin was synthesized as an internal standard for use in a LC/MS/MS method developed for the simultaneous quantitative determination of the drug in human serum. d3-Cerivastatin was efficiently prepared on large scale from d

Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists

5-Hydroxyalkyl-4-phenylpyridines have been identified as a novel class of glucagon antagonists with potential utility for the treatment of diabetes. A lead structure with moderate activity was discovered through a high throughput screening assay. Structure-activity relationships led to the discovery of a potent antagonist, IC50=0.11 μM, more than 60-fold improvement over the lead structure.

Substituted biphenyls

Substituted biphenyls having glucagon receptor antagonistic activity. Claimed compounds have the formula wherein R1aand R1bindependently represent (C1-C6) alkyl; R2represents (C1-C10) alkyl or substituted (C1-C10) alkyl wherein the substituents are independently from 1 to 3 of —SR7; R7represents phenyl, or substituted phenyl wherein the substituents are independently 1-5 of halogen, trifluoromethyl, (C1-C6) alkyl, (C1-C6) alkoxy, nitro, cyano, or hydroxyl; R3represents substituted (C1-C6) alkyl wherein the substituents are 1-2 hydroxyl groups; G represents a substituent selected from the group consisting of halogen, (C1-C6) alkyl, and OR4wherein R4is H or (C1-C6) alkyl; and y is 0 or an integer of 1-3. Pharmaceutical compositions containing such compounds and methods of treatment of glucagon-mediated conditions by administering such compounds are also claimed.

7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis

Novel compounds for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis of the formula STR1 in which A, B, D and E can have varied meanings, X is --CH2 --CH2 or --CH=CH--, and R is STR2 wherein R21 denotes hyd

CERTAIN 7-[2,6-DIISOPROPYL-4-PHENYL-5-LOWER ALKOXYMETHYL-PYRID-3-YL]-3,5-DIHYDROXY-6-ENOATES AND DERIVATIVES USEFUL FOR TREATING CIRCULATORY DISEASES

Novel compounds for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis of the formula (I) in which A, B, D and E can have varied meanings, X is -CH2-CH2 or -CH=CH-, and R is wherein R21 denotes hydrogen or alkyl and R22 denotes hydrogen, denotes alkyl, aryl or aralkyl, or denotes a cation, and their oxidation products

HMG-COA REDUCTASE-INHIBITING IMINO-SUBSTITUTED PYRIDINES

HMG-CoA reductase-inhibiting imino-substituted pyridines of the formula STR1 in which R 1 is optionally substituted aryl, R 2 is optionally substituted aryl or alkyl, OH, alkoxy, aralkoxy, or optionally substituted aryloxy,R. sup.

Certain 2,6-diisopropyl-4-(4-fluoro-phenyl)-3,5-bis-dimethyl-3',5'-dihydroxy-hept-6-enoate-pyridine derivatives useful for treating lipoproteinaemia and arteriosclerosis

For the treatment of lipoproteinaemia and arteriosclerosis, the new disubstituted pyridines of the formula STR1 in which R1 is optionally substituted aryl or heteroaryl, R2 is cycloalkyl or optionally substituted alkyl, R3